Länsförsäkringar

Founded in 1844, Länsförsäkringar is a Swedish insurance company headquartered in Stockholm. It offers a wide array of banking, insurance, and real estate services to its clients.

Niclas Ekestubbe

Investment Manager of Alternative Investments

Past deals in Sweden

Phenaros Pharmaceuticals

Pre Seed Round in 2025
Phenaros Pharmaceuticals is a Swedish spin-off drug discovery company from Uppsala University. We employ phenomics (large-scale cell morphological profiling) in conjunction with automation and AI to discover and repurpose medications for uncommon diseases. Aside from developing an in-house drug discovery pipeline, we also form collaborations to provide access to our discovery platform.

Stendorren Fastigheter

Post in 2024
Stendorren Fastigheter specializes in the development, ownership, operation, and maintenance of industrial, logistics, and warehouse facilities across Nordic growth regions. It focuses primarily on Greater Stockholm and Malardalen, offering suitable spaces at competitive lease terms to its tenants.

Swedish Logistic Property

Post in 2024
Swedish Logistic Property specializes in developing and managing logistics properties across Sweden. Its portfolio comprises strategically located, energy-efficient facilities tailored to meet diverse business needs. The company focuses on acquiring and developing new properties while prioritizing sustainability in construction practices and facility operations.

Swedish Logistic Property

Post in 2023
Swedish Logistic Property specializes in developing and managing logistics properties across Sweden. Its portfolio comprises strategically located, energy-efficient facilities tailored to meet diverse business needs. The company focuses on acquiring and developing new properties while prioritizing sustainability in construction practices and facility operations.

Adenovir Pharma

Venture Round in 2010
Founded in 2008, Adenovir Pharma is a Swedish biotechnology company specializing in the development of new treatments for infectious eye diseases. Its primary focus is on epidemic keratoconjunctivitis (EKC), utilizing unique patented technology and product concepts to offer innovative solutions to the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.